Abstract
HER2 is a 185 kDa transmembrane glycoprotein in the receptor tyrosine kinase family that also includes EGFR or HER1 (erbB1), HER3 (erbB3), and HER4 19 (erbB4). HER2 gene amplification and protein overexpression is seen in 20-25% of breast cancers. HER2 protein overexpression is an independent predictor of poor prognosis, thus, the receptor has become a focus for several novel types of targeted therapies. Some patients whose tumors overexpress HER2 develop immunity directed against the protein. Immunotherapeutic approaches aimed at generating or augmenting immunity to HER2 have been also been developed.
Author supplied keywords
- Adoptive T cell therapy
- Assessment
- FISH assay
- Gene amplification
- Human epidermal growth factor receptor 2 (HER2)
- Immunogenic in cancer
- Immunohistochemistry
- In cancer
- Inhibitors
- Lapatinib
- Neratinib
- PI3K/AKT and RAS-MAPK pathways
- Pertuzumab
- Plasmid DNAvaccines
- Preclinical studies
- Trastuzumab
- Trastuzumab-DM1 (T-DM1)
- Vaccines
- erbB2/neu. See Human epidermal growth factor receptor 2 (HER2)
Cite
CITATION STYLE
Disis, M. L., & O’Meara, M. M. (2017). HER2/neu. In Cancer Therapeutic Targets (Vol. 1–2, pp. 267–275). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_46
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
